Update publication information. As a first-line drug for treating advanced hepatocellular carcinoma, the resistance to sorafenib has always attracted attention. However, most attention has been focused on a series of mechanisms related to drug resistance caused after sorafenib treatment. In this study, we used proteomic techniques to explore the potential mechanisms by which pre-treatment factors affect sorafenib resistance.